AC Immune
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 161
- Market Cap
- $302.7M
- Website
- http://www.acimmune.com
- Introduction
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Parkinson Immunotherapy ACI-7104.056 Demonstrates Positive Antibody Responses in ...
AC Immune SA's phase 2 VacSYn trial shows ACI-7104.056, an anti-alpha-synuclein active immunotherapy, induces positive antibody responses in Parkinson disease patients after 6 weeks. The study may expand to Part 2 in H1 2025 based on interim results.
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
AC Immune SA to present at Jefferies 2024 London Healthcare Conference on Nov 20, 2024, featuring a fireside chat and investor meetings. Webcast available on AC Immune’s website.
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Climb Bio appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who remains a director. Dr. Williams brings over 30 years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen.
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune reports Q3 2024 financials: CHF 157.9M cash, JNJ-2056 Fast Track designation, CHF 24.6M milestone payment, and Phase 2 VacSYn trial on track for PD.
7 Alzheimer's and Parkinson's Programs Discarded in 2024
Despite approvals for Leqembi and Kisunla, attrition in Alzheimer’s and Parkinson’s pipelines persists, with Roche, Johnson & Johnson, Sage Therapeutics, and Otsuka discontinuing programs. Analysts attribute these decisions to clinical trial data and evolving commercial opportunities, noting the Alzheimer’s market is projected to be worth $15.5 billion by 2031, while Parkinson’s drugs are expected to reach $6.63 billion by 2029.
Roche leaves Alzheimer partnership with UCB
Roche ends Alzheimer’s partnership with UCB, returning rights to Phase 2a candidate bepranemab. This marks Roche's third Alzheimer’s candidate termination this year, following similar actions with AC Immune. Despite setbacks, Roche remains active in early Alzheimer’s diagnosis.
© Copyright 2025. All Rights Reserved by MedPath